Análisis de la acción Zevra Therapeutics Inc (ZVRA)ZVRAZevra Therapeutics Inc

Zevra Therapeutics, Inc. is a commercial-stage rare disease company with a late-stage pipeline committed to bringing therapeutics to people living with rare diseases. Its commercial products and active development assets are MIPLYFFA, Arimoclomol, OLPRUVA, and Celiprolol. Its lead product, Niemann-Pick disease type C (NPC), is a rare, progressive neurodegenerative disorder. NPC is an ultra-rare and progressive neurodegenerative disease characterized by an inability of the body to transport cholesterol and lipids inside of cells. OLPRUVA (sodium phenylbutyrate) for oral suspension is approved in the United States as adjunctive therapy to standard of care, which includes dietary management, for the chronic management of UCDs involving deficiencies of carbamylphosphate synthetase, ornithine transcarbamylase, or argininosuccinic acid synthetase. Celiprolol is a selective adrenoceptor modulator (SAM). Celiprolol is approved in certain EU states for the treatment of hypertension and angina. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Currently, Zevra Therapeutics Inc (ZVRA) is trading at $9.81, which is significantly lower than the analyst price targets of $23 and $28. However, the RSI is at 29.51, indicating that the stock is oversold, which could present a buying opportunity in the future. The company reported a strong revenue growth of 53% year-over-year in Q2 2026, with net revenue reaching $39.7 million, driven by MIPLYFFA sales. The main risk is the recent rejection of their drug application by the EMA, which could impact future revenue growth.